HEALTH TECHNOLOGY ASSESSMENT AND PERSONALIZED MEDICINE: ARE ECONOMIC EVALUATION GUIDELINES SUFFICIENT TO SUPPORT DECISION MAKING?

被引:28
|
作者
Husereau, Don [1 ]
Marshall, Deborah A. [2 ]
Levy, Adrian R. [3 ]
Peacock, Stuart [4 ]
Hoch, Jeffrey S. [5 ]
机构
[1] Univ Ottawa, Univ Hlth Sci Med Informat & Technol, Inst Hlth Econ, Dept Epidemiol & Community Med, Ottawa, ON K1N 6N5, Canada
[2] Univ Calgary, Fac Med, Dept Community Hlth Sci, Calgary, AB T2N 4Z6, Canada
[3] Dalhousie Univ, Fac Med, Dept Community Hlth & Epidemiol, Halifax, NS B3H 1V7, Canada
[4] Univ British Columbia, Canadian Ctr Applied Res Canc Control, British Columbia Canc Res Ctr, Sch Populat & Publ Hlth, Vancouver, BC V6T 1Z3, Canada
[5] Canadian Ctr Appl Res Canc Control, Pharmacoecon Res Unit, Canc Care Ontario, Toronto, ON M5G 2L7, Canada
关键词
Costs and cost analysis; Biomedical research/methods; Biomedical research/standards; Decision support techniques; Delivery of health care; Diagnostic techniques and procedures; Health policy; Humans; Individualized medicine/methods; Technology assessment; Biomedical; COST-EFFECTIVENESS ANALYSIS; BREAST-CANCER; HETEROGENEITY; FRAMEWORK; TESTS; WOMEN;
D O I
10.1017/S0266462314000142
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Many jurisdictions delivering health care, including Canada, have developed guidance for conducting economic evaluation, often in the service of larger health technology assessment (HTA) and reimbursement processes. Like any health intervention, personalized medical (PM) interventions have costs and consequences that must be considered by reimbursement authorities with limited resources. However, current approaches to economic evaluation to support decision making have been largely developed from population-based approaches to therapy-that is, evaluating the costs and consequences of single interventions across single populations. This raises the issue as to whether these methods, as they are or more refined, are adequate to address more targeted approaches to therapy, or whether a new paradigm for assessing value in PM is required. Objectives: We describe specific issues relevant to the economic evaluation of diagnostics-based PM and assess whether current guidance for economic evaluation is sufficient to support decision making for PM interventions. Methods: Issues were identified through literature review and informal interviews with national and international experts (n = 10) in these analyses. This article elaborates on findings and discussion at a workshop held in Ottawa, Canada, in January 2012. Results: Specific issues related to better guiding economic evaluation of personalized medicine interventions include: how study questions are developed, populations are characterized, comparators are defined, effectiveness is evaluated, outcomes are valued and how resources are measured. Diagnostics-based PM also highlights the need for analyses outside of economic evaluation to support decision making. Conclusions: The consensus of this group of experts is that the economic evaluation of diagnostics-based PM may not require a new paradigm. However, greater complexity means that existing approaches and tools may require improvement to undertake these more analyses.
引用
收藏
页码:179 / 187
页数:9
相关论文
共 50 条
  • [31] Economic evidence in decision-making process in laboratory medicine
    Brunetti, Massimo
    Pregno, Silvia
    Schuenemann, Holger
    Plebani, Mario
    Trenti, Tommaso
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 (04) : 617 - 621
  • [32] SUSTAINABILITY DECISION-MAKING BY USING TECHNOLOGY ASSESSMENT
    Tulbure, Ildiko
    ECOLOGY, ECONOMICS, EDUCATION AND LEGISLATION CONFERENCE PROCEEDINGS, SGEM 2016, VOL III, 2016, : 577 - 584
  • [33] Methods, procedures, and contextual characteristics of health technology assessment and health policy decision making: Comparison of health technology assessment agencies in Germany, United Kingdom, France, and Sweden
    Schwarzer, Ruth
    Siebert, Uwe
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2009, 25 (03) : 305 - 314
  • [34] A national study of breast and colorectal cancer patients' decision-making for novel personalized medicine genomic diagnostics
    Issa, Amalia M.
    Tufail, Waqas
    Atehortua, Nelson
    McKeever, John
    PERSONALIZED MEDICINE, 2013, 10 (03) : 245 - 256
  • [35] Patient and public involvement in health technology decision-making processes in Brazil
    de Freitas Lopes, Ana Carolina
    Dutilh Novaes, Hillegonda Maria
    de Soarez, Patricia Coelho
    REVISTA DE SAUDE PUBLICA, 2020, 54 : 1 - 10
  • [36] The preliminary economic evaluation of health technologies for the prioritization of health technology assessments - A discussion
    Harper, G
    Townsend, J
    Buxton, M
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 1998, 14 (04) : 652 - 662
  • [37] Introducing Economic Evaluation as a Decision Support Tool in Health Care: A Case Review of IR Iran
    Baghbanian, Abdolvahab
    Esmaeili, Saeed
    HEALTH SCOPE, 2012, 1 (03): : 101 - 109
  • [38] Methodological guidelines and publications of benefit-risk assessment for health technology assessment: a scoping review
    Suzumura, Erica Aranha
    de Oliveira Ascef, Bruna
    Maia, Fernando Henrique de Albuquerque
    Bortoluzzi, Aline Frossard Ribeiro
    Domingues, Sidney Marcel
    Farias, Natalia Santos
    Gabriel, Franciele Cordeiro
    Jahn, Beate
    Siebert, Uwe
    de Soarez, Patricia Coelho
    BMJ OPEN, 2024, 14 (06):
  • [39] Evaluation of a shared decision making educational program: The Ottawa Decision Support Tutorial
    Boland, Laura
    Legare, France
    Carley, Meg
    Graham, Ian D.
    O'Connor, Annette M.
    Lawson, Margaret L.
    Stacey, Dawn
    PATIENT EDUCATION AND COUNSELING, 2019, 102 (02) : 324 - 331
  • [40] Who Does the Numbers? The Role of Third-Party Technology Assessment to Inform Health Systems' Decision-Making about the Funding of Health Technologies
    Barbieri, Marco
    Hawkins, Neil
    Sculpher, Mark
    VALUE IN HEALTH, 2009, 12 (02) : 193 - 201